Twelve-year nationwide cohort study identifying risk factors for conversion from mild cognitive impairment to

Kyoungwon Baik1,2, Minwoong Kang3, Yu Jeong Park4

  • 1Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Scientific Reports
|October 10, 2025
PubMed

Insights

This study found that being underweight, certain cardiometabolic diseases, depression, and physical inactivity increase the risk of mild cognitive impairment (MCI) progressing to dementia of the Alzheimer

Area of Science:

  • Neuroscience
  • Gerontology
  • Public Health

Background:

  • Mild cognitive impairment (MCI) is a critical pre-dementia stage.
  • Identifying risk factors for progression to dementia of the Alzheimer's type (DAT) is crucial for early intervention.
  • Previous studies on MCI to DAT conversion risk factors have yielded inconsistent results.

Purpose of the Study:

  • To investigate the incidence of DAT conversion in Korean patients with MCI.
  • To identify specific risk factors associated with DAT conversion in this population.
  • To inform the development of preventive strategies for MCI progression.

Main Methods:

  • A 12-year nationwide retrospective cohort study.
  • Inclusion of patients aged ≥40 years diagnosed with MCI between 2009 and 2015.
  • Analysis of DAT conversion incidence and risk factors using Cox proportional hazards regression.

Main Results:

  • DAT conversion rates increased with age, peaking between 70-90 years.
  • Underweight status, diabetes, coronary heart disease, and hemorrhagic stroke were associated with increased DAT conversion risk.
  • Depression and physical inactivity significantly elevated DAT conversion risk.
  • Mild to moderate alcohol consumption, high income, and urban residence were linked to a decreased risk of DAT conversion.

Conclusions:

  • Multiple modifiable factors, including lifestyle and socioeconomic status, significantly influence MCI to DAT conversion.
  • Understanding these risk factors is essential for targeted preventive measures.
  • The findings provide a basis for public health initiatives aimed at reducing dementia incidence in MCI patients.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
772
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
517
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822